Home / Business and Economy / Sino Biopharm Buys RNA Drug Developer Hygieia
Sino Biopharm Buys RNA Drug Developer Hygieia
13 Jan
Summary
- Sino Biopharmaceutical will acquire Hangzhou Hygieia for up to 1.20 billion yuan.
- The deal aims to expand Sino Biopharmaceutical's chronic disease treatment portfolio.
- Hygieia specializes in small interfering RNA therapies for metabolism and neurological disorders.
Sino Biopharmaceutical has announced its intent to acquire Hangzhou Hygieia Biomedical for a maximum of 1.20 billion yuan, approximately $172.04 million. This acquisition, finalized on Tuesday, January 13, 2026, is a key step in bolstering the company's offerings in chronic-disease treatments.
The deal involves a unit of Sino Biopharmaceutical purchasing a 100% stake in Hygieia. Consideration will be a mix of cash and newly issued shares, making Hygieia a subsidiary. This follows Sino Biopharmaceutical's recent expansion into innovative drug pipelines, including a prior agreement with LaNova Medicines.
Hygieia is recognized for its development of small interfering RNA therapies, possessing a comprehensive platform from target discovery to clinical proof-of-concept. The company's research is particularly focused on critical areas such as weight management, metabolism, cardiovascular and cerebrovascular diseases, and neurological disorders.
